RxSight, Inc.
RXST
Positions held
Your positionsRXST isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $201.73M | Enterprise value | $3.51M | Trailing P/E | — | Forward P/E | -6.96 |
| PEG | — | Price / book | 0.77 | Beta | 1.14 | Dividend yield | 0.00% |
| Revenue growth | 0.3% | Earnings growth | — | Gross margin | 77.5% | Operating margin | -40.8% |
| Profit margin | -36.8% | ROE | -17.3% | ROA | -10.4% | Debt / equity | 0.04 |
| Current ratio | 4.07 | Free cash flow | -$6.73M | Analyst recommendation | none | Mean target | $7.57 |
| 52w high | $13.22 | 52w low | $4.48 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $33.7M | $30.9M | $32.6M | $30.3M | $33.6M |
| Op margin | -40.8% | -57.7% | -34.8% | -40.1% | -41.6% |
| Net income | -$12.1M | -$15.9M | -$9.2M | -$9.8M | -$11.8M |
| Gross margin | 76.7% | 76.1% | 77.5% | 79.9% | 74.9% |
| Gross profit | $25.9M | $23.5M | $25.3M | $24.2M | $25.2M |
| Operating income | -$13.8M | -$17.8M | -$11.3M | -$12.2M | -$14.0M |
- Revenue +9% vs prior quarter ($34M vs $31M).
- Gross margin 76.7% (was 76.1% prior quarter).
- Operating margin expanded to -40.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $134M | $140M | $89.1M | $49.0M | — |
| Op margin | -35.8% | -26.3% | -56.2% | -129.2% | — |
| Net income | -$38.9M | -$27.5M | -$48.6M | -$66.8M | — |
| Gross margin | 76.6% | 70.7% | 60.4% | 43.5% | — |
| Gross profit | $103M | $98.9M | $53.8M | $21.3M | — |
| Operating income | -$48.2M | -$36.9M | -$50.1M | -$63.3M | — |
Headlines — watch
• [WARN · fundamentals] RxSight (RXST) Stock Fair Value Falls After Soft Q2 Trends And Guidance Cut
News
2026-09-23 · RxSight's Utilization-Growth Upside Faces Structural, Competitive Headwinds, BofA Says
2026-09-22 · BofA Adjusts Price Target on RxSight to $5.50 From $6.50
2026-08-26 · RxSight, Inc. to Participate in the Wells Fargo Healthcare Conference
2026-08-13 · Could Alcon (ALC) and RxSight (RXST)’s Partnership Reshape the Future of Cataract Surgery?
2026-08-12 · RxSight (RXST) Q2 2026 Earnings Call Transcript
2026-08-06 · Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 519% Upside
2026-08-06 · RxSight Inc (RXST) (Q2 2026) Earnings Call Highlights: Strategic Pivot Amid Revenue Decline and ...
2026-08-06 · RxSight Q2 Earnings Call Highlights
2026-08-05 · RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
2026-08-05 · RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
2026-07-29 · Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline
2026-07-28 · UBS Adjusts Price Target on RxSight to $5.50 From $9, Maintains Neutral Rating
Price (daily)
Full chart · RSI · MACD · patterns